Secnidazole: A Review of its Antimicrobial Activity, Pharmacokinetic Properties and Therapeutic Use in the Management of Protozoal Infections and Bacterial Vaginosis

Drugs

Volumn 51, Issue 4, 1996, Pages 621-638

  Gillis, Jane C ^a   Wiseman, Lynda R ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIA (MICROORGANISMS); ATAXIA;

METRONIDAZOLE; SECNIDAZOLE; TINIDAZOLE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AMEBIASIS; ANOREXIA; ANTIBACTERIAL ACTIVITY; ANTIMICROBIAL ACTIVITY; ATAXIA; CHILD; DRUG ABSORPTION; DRUG EFFICACY; DRUG ERUPTION; DRUG METABOLISM; EOSINOPHILIA; EPIGASTRIC PAIN; ERYTHEMA; EYELID EDEMA; GASTROINTESTINAL SYMPTOM; GIARDIASIS; GLOSSITIS; HEADACHE; HUMAN; HYPERSALIVATION; LYMPHOCYTOSIS; NAUSEA; NEUTROPHILIA; PARESTHESIA; PROTOZOAL INFECTION; REVIEW; TASTE DISORDER; TRICHOMONIASIS; VAGINITIS; VERTIGO; VOMITING; VULVA DISEASE;

ABSORPTION; CLINICAL TRIALS; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; METRONIDAZOLE; PROTOZOAN INFECTIONS; TISSUE DISTRIBUTION; VAGINOSIS, BACTERIAL;

EID: 0029913196     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199651040-00007     Document Type: Review

References (56)

1. Rossignol JF, Maisonneuve H, Cho YW. Nitroimidazoles in the treatment of trichomoniasis, giardiasis, and amebiasis. Int J Clin Pharmacol Ther Toxicol 1984 Feb; 22: 63-72
2. Edwards DI. Nitroimidazole drugs - action and resistance mechanisms. I. Mechanisms of action. J Antimicrob Chemother 1993; 31: 9-20
3. Müller M. Action of clinically utilized 5-nitroimidazoles on microorganisms. Scand J Infect Dis 1981 Suppl. 26: 31-41
4. Jokipii L, Jokipii AMM. Comparative evaluation of the 2-methyl-5-nitroimidazole compounds dimetridazole, metronidazole, secnidazole, ornidazole, tinidazole, carnidazole, and panidazole against Bacteroides fragilis and other bacteria of the Bacteroides fragilis group. Antimicrob Agents Chemother 1985 Oct; 28: 561-4
5. Symonds J. Secnidazole - a nitroimidazole with a prolonged serum half-life [letter]. J Antimicrob Chemother 1979 Jul; 5: 484-6
6. Videau D, Niel G, Siboulet A, et al. Secnidazole. A 5-nitroimidazole derivative with a long half-life. Br J Vener Dis 1978 Apr; 54: 77-80
7. Ray DK, Tendulkar JS, Shrivastava VB, et al. A metronidazole-resistant strain of Trichomonas vaginalis and its sensitivity to Go 10213. J Antimicrob Chemother 1984 Oct; 14: 423-6
8. Andre LJ. Treatment of amoebiasis by secnidazole [in French]. Ann Gastroenterol Hepatol 1979; 15 (3): 221-5
9. Favennec L, Chochillon C, Magne D, et al. A new screening assay for antigiardial compounds: effects of various drugs on the adherence of Giardia duodenalis to Caco2 cells. Parasitol Res 1992; 78: 80-1
10. Botero D, Abreu Martin L, Cardoso Salles JM. Efficacy and safety of a single dose of secnidazole in the treatment of acute uncomplicated intestinal amoebiasis in Latin America: a multicentre study. In: Katz N, Willis AT, editors. Secnidazole: a new approach in 5-nitroimidazole therapy. Proceedings from the 16th International Congress of Chemotherapy; 1989 June 12; Jerusalem. Amsterdam: Excerpta Medica, 1989: 49-55
11. Abreu Martin L, Paz Moreno L. Single-dose secnidazole versus two-day therapy with tinidazole in the treatment of intestinal amoebiasis. In: Katz N, Willis AT, editors. Secnidazole: a new approach in 5-nitroimidazole therapy. Proceedings from the 16th International Congress of Chemotherapy; 1989 June 12; Jerusalem. Amsterdam: Excerpta Medica, 1989: 56-62
12. Sinuhaji AB, Lubis CP, Daulay HRM, et al. A double blind trial between metronidazole and secnidazole in acute amebic dysentery in children (preliminary report). Paediatr Indones 1986 Jan-Feb; 26: 9-14
13. Latonio AA. Efficacy of a single dose of secnidazole in the treatment of acute and chronic amoebiasis. J Trop Med Hyg 1988 Aug; 91: 202-4
14. Katz N, Cimerman B, Zingano AG, et al. A clinical trial using secnidazole suspension in children infected with Giardia lamblia. In: Katz N, Willis AT, editors. Secnidazole: a new approach in 5-nitroimidazole therapy. Proceedings from the 16th International Congress of Chemotherapy; 1989 June 12; Jerusalem. Amsterdam: Excerpta Medica, 1989: 35-40
15. Cimerman B, Boruchovski H, Cury FM, et al. A comparative study of secnidazole and metronidazole in the treatment of giardiasis. In: Katz N, Willis AT, editors. Secnidazole: a new approach in 5-nitroimidazole therapy. Proceedings from the 16th International Congress of Chemotherapy; 1989 June 12; Jerusalem. Amsterdam: Excerpta Medica, 1989: 28-34
16. Bravo AA, Vázquez RQ, Farrugia DL. Tratamiento de la vaginitis por tricomonas, con secnidazol en dosis úniea. Invest Med Int 1978; 5: 476-82
17. Siboulet A, Catalan F, Videau D, et al. La trichomonase urogénitale. Essais d'un imidazole à demi-vie longue: le secnidazole. Med Mal Infect 1977; 7: 400-9
18. Piato A, Cymbalista N. Tratamento da tricomoníase com dose única de secnidazol (14.539 R.P.). Rev Bras Med 1977 April; 34 (4): 197-200
19. Rocha AM, Sarraff Neto A. Tratamento da tricomoniase urogenital (ensaio clínico o 14.539 RP (secnidazol). Rev Bras Med 1977 June; 34 (6): 365-6
20. Machado D, Machado LE. A single dose of secnidazole in the treatment of vaginal trichomoniasis: a comparative study of morning and evening doses. In: Katz N, Willis AT, editors. Secnidazole: a new approach in 5-nitroimidazole therapy. Proceedings from the 16th International Congress of Chemotherapy; 1989 June 12; Jerusalem. Amsterdam: Excerpta Medica, 1989: 71-7
21. Dupouy-Camet J. Single dose treatments in tropical infectious diarrhoea: the place of secnidazole. Drug Invest 1994; 8 Suppl. 1: 35-46
22. Van Reken DE, Pearson RD. Antiparasitic Agents. In: Mandell GL, Douglas Jr RG, Bennett JE, editors. Principles and practice of infectious diseases. 3rd ed. New York: Churchill Livingstone, 1990: 398-427
23. Moreno SN, Mason RP, Muniz RP, et al. Generation of free radicals from metronidazole and other nitroimidazoles by Tritrichomonas foetus. J Biol Chem 1983 Apr 10; 258: 4051-4
24. Roe FJC. Safety of nitroimidazoles. Scand J Infect Dis 1985; 46: 72-81
25. Lossick JG, Kent HL. Trichomoniasis: trends in diagnosis and management. Am J Obstet Gynecol 1991 Oct; 165 (4): 1217-22
26. Müller M, Lossick JG, Gorrell TE. In vitro susceptibility of Trichomonas vaginalis to metronidazole and treatment outcome in vaginal trichomoniasis. Sex Transm Dis 1988 Jan-Mar; 15 (1): 17-24
27. The nitroimidazole family of drugs [editorial]. Br J Vener Dis 1978; 54: 69-71
28. Populaire P, Decouvelaere B, Renard A, et al. Study of seric concentrations and urinary excretion of secnidazole after oral administration in the man. Comparison with tinidazole [in French]. Pathol Biol Paris 1980; 28: 621-4
29. Frydman AM, Lemar M, Le Roux Y, et al. A review of the pharmacokinetics of secnidazole in man. In: Katz N, Willis AT, editors. Secnidazole: a new approach in 5-nitroimidazole therapy. Proceedings from the 16th International Congress of Chemotherapy: 1989 June 12; Jerusalem. Amsterdam: Excerpta Medica, 1989: 12-26
30. Tenenbaum H, Cuisinier FJG, Le Liboux A, et al. Secnidazole concentrations in plasma and crevicular fluid after a single oral dose. J Clin Periodontol 1993 Aug; 20: 505-8
31. Rhóre-Poulenc Rorer. Secnidazole prescribing information.
32. Maurice M, Pichard L, Daujat M, et al. Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture. FASEB J 1992 Jan 6; 6: 752-8
33. DuPont HL. Prevention and treatment strategies in giardiasis and amoebiasis. Drug Invest 1994; 8 Suppl. 1: 19-25
34. Plorde JJ. Giardiasis. In: Wilson JD, Braunwald E, et al., editors, Harrison's principles of internal medicine. 12th ed. v. 1. New York: McGraw-Hill Inc., 1991: 802-3
35. Protezoan intestinal infections. WHO Drug Info 1988; 2 (4): 200-5
36. Anandan JV. Parasitic diseases. In: DiPiro JT, Talbert RL, et al., editors. Pharmacotherapy a physiologic approach. New York: Elsevier, 1989: 1194-213
37. Sobe JD. Management of vaginosis. Drug Invest 1994; 8 Suppl. 1: 26-34
38. Lossick JG. Treatment of sexually transmitted vaginosis/vaginitis. Rev Infect Dis 1990 July-August; 12 Suppl. 6: S665-80
39. Plorde JJ. Amebiasis. In: Wilson JD, Braunwald E, et al., editors. Harrison's principles of internal medicine. 12th ed. v 1. New York: McGraw-Hill Inc, 1991: 778-81
40. Brucker G. Prevalence of amoebiasis and giardiasis in severe intestinal disorders in intertropical countries. In: Katz N, Willis AT, editors. Secnidazole: a new approach in 5-nitroimidazole therapy. Proceedings from the 16th International Congress of Chemotherapy; 1989 June 12; Jerusalem. Amsterdam: Excerpta Medica, 1989: 3-11
41. Cooperstock M, DuPont HL, Corrado ML, et al. Evaluation of new anti-infective drugs for the treatment of diarrhea caused by Giardia lamblia. Clin Infect Dis 1992; 15 Suppl. 1: S244-8
42. Cooperstock M, DuPont HL, Corrado ML, et al. Evaluation of new anti-infective drugs for the treatment of diarrhea caused by Entamoeba histolytica. Clin Infect Dis 1992; 15 Suppl. 1: S254-8
43. Botero D. An overview of the clinical experience of secnidazole in giardiasis and amoebiasis. Drug Invest 1994; 8 Suppl. 1: 47-52
44. Huggins D, de Almeida SB, Cheng TK, et al. A news chemotherapies agents (drugs) for treatment of parasites infections: albendazole and secnidazole [in Portuguese]. Rev Bras Med 1991; 48 (6): 310-8
45. Cunha AS, Silva EF, Raso P, et al. Clinical trial with the imidazol compound R.P. 14539, in intestinal amebiasis [in Portuguese]. Rev Inst Med Trop Sao Paulo 1977 September-Oetober; 19 (5): 342-8
46. Gorbea Robles MC, Eternod JG, Valázquez FG, et al. Estudio comparative en amebiasis y giardiasis intestinal del lactante y pre-escolar: eficacia y tolerancia del secnidazol vs metronidazol y etofamida. Invest Med Int 1989; 16: 79-82
47. Soedin K, Syukran OKA, Fadillah A, et al. Comparison between the efficacy of a single dose of secnidazole with a 5-day course of tetracycline and clioquinol in the treatment of acute intestinal amoebiasis. Pharmatherapeutica 1985; 4: 251-4
48. Soedin K, Lelo A. A single dose of secnidazole vs a 5-day regimen of the combination tetracycline/clioquinol in the treatment of intestinal amoebiasis. In: Katz N, Willis AT, editors. Secnidazole: a new approach in 5-nitroimidazole therapy. Proceedings from the 16th International Congress of Chemotherapy; 1989 June 12; Jerusalem. Amsterdam: Excerpta Medica, 1989: 43-8
49. Holmes KK, Handsfield HH. Sexually transmitted diseases. In: Wilson JD, Braunwald E, et al., editors. Harrison's principles of internal medicine. 12th ed. v. 1. New York: McGraw-Hill Inc., 1991: 524-33
50. Sawyer PR, Brogden RN, Pinder RM, et al. Tinidazole: a review of its antiprotozoal activity and therapeutic efficacy. Drugs 1976; 11 (6): 423-40
51. Bagnoli VR. An overview of the clinical experience with secnidazole in bacterial vaginosis and trichomoniasis. Drug Invest 1994; 8 Suppl. 1: 53-60
52. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines. MMWR Morb Mortal Wkly Rep 1993; 42 (No. RR-14): 67-71
53. Bagnoli VR, Kesselring GL. Multicenter study, double-blind, randomized comparative between secnidazole and tinidazole in the treatment of non-specific vaginitis [in Portuguese]. Rev Bras Med 1992; 111 (4): 198-202
54. Hegg R, Ribeiro RM, Bagnoli VR, et al. Treatment of non-specific vaginitis with secnidazole and metronidazole. In: Katz N, Willis AT, editors. Secnidazole: a new approach in 5-nitroimidazole therapy. Proceedings from the 16th International Congress of Chemotherapy; 1989 June 12: Jerusalem. Amsterdam: Excerpta Medica, 1989: 65-70
55. Cook GC. Amoebiasis and giardiasis. Drug Invest 1994; 8 Suppl. 1: 1-18
56. Meingassner JG, Heyworth PG. Intestinal and urogenital flagellates. Antibiot Chemother 1981; 30: 163-202